{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:25:54Z","timestamp":1793744754503,"version":"4.6.1"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1097\/wnf.0000000000000063","type":"journal-article","created":{"date-parts":[[2015,1,12]],"date-time":"2015-01-12T05:48:11Z","timestamp":1421041691000},"page":"11-17","source":"Crossref","is-referenced-by-count":102,"title":["N-Acetylcysteine as an Adjunctive Therapy to Risperidone for Treatment of Irritability in Autism"],"prefix":"10.1097","volume":"38","author":[{"given":"Mohammadali","family":"Nikoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanieh","family":"Radnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Farokhnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad-Reza","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahin","family":"Akhondzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"2","key":"R2-3-20210203","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2174\/157488507780619095","article-title":"Autism spectrum disorders: etiology and pharmacotherapy.","volume":"2","author":"Mohammadi","year":"2007","journal-title":"Curr Drug Therapy"},{"key":"R3-3-20210203","first-page":"1","article-title":"Prevalence of autism spectrum disordersAutism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008.","volume":"61","author":"Baio","year":"2012","journal-title":"MMWR Surveill Summ"},{"issue":"2","key":"R4-3-20210203","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/10673220802075852","article-title":"Pharmacological treatment options for autism spectrum disorders in children and adolescents.","volume":"16","author":"Leskovec","year":"2008","journal-title":"Harv Rev Psychiatry"},{"key":"R5-3-20210203","doi-asserted-by":"crossref","first-page":"e1312","DOI":"10.1542\/peds.2011-0427","article-title":"A systematic review of medical treatments for children with autism spectrum disorders.","volume":"127","author":"McPheeters","year":"2011","journal-title":"Pediatrics"},{"issue":"1","key":"R6-3-20210203","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.pcl.2010.10.011","article-title":"Psychopharmacology of autistic spectrum disorders in children and adolescents.","volume":"58","author":"Nazeer","year":"2011","journal-title":"Pediatr Clin North Am"},{"issue":"4","key":"R7-3-20210203","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1750-3639.2007.00102.x","article-title":"The neurobiology of autism.","volume":"17","author":"Pardo","year":"2007","journal-title":"Brain Pathol"},{"issue":"1","key":"R8-3-20210203","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3109\/1547691X.2010.545086","article-title":"Theoretical aspects of autism: causesa review.","volume":"8","author":"Ratajczak","year":"2011","journal-title":"J Immunotoxicol"},{"issue":"5","key":"R9-3-20210203","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1034\/j.1601-183X.2003.00037.x","article-title":"Model of autism: increased ratio of excitationinhibition in key neural systems.","volume":"2","author":"Rubenstein","year":"2003","journal-title":"Genes Brain Behav"},{"key":"R10-3-20210203","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/sj.mp.4001499","article-title":"Autism as a disorder of neural information processing: directions for research and targets for therapy.","volume":"9","author":"Belmonte","year":"2004","journal-title":"Mol Psychiatry"},{"key":"R11-3-20210203","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.2174\/092986712802002572","article-title":"Glutathione-related factors and oxidative stress in autism, a review.","volume":"19","author":"Ghanizadeh","year":"2012","journal-title":"Curr Med Chem"},{"key":"R12-3-20210203","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1212\/WNL.57.9.1618","article-title":"Postmortem brain abnormalities of the glutamate neurotransmitter system in autism.","volume":"57","author":"Purcell","year":"2001","journal-title":"Neurology"},{"key":"R13-3-20210203","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0006-3223(02)01430-0","article-title":"Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal and cerebellar cortices.","volume":"52","author":"Fatemi","year":"2012","journal-title":"Biol Psychiatry"},{"key":"R14-3-20210203","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.pnpbp.2006.06.013","article-title":"Increased serum levels of glutamate in adult patients with autism.","volume":"30","author":"Shinohe","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R15-3-20210203","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s10803-011-1314-x","article-title":"Distinct plasma profile of polar neutral amino acids, leucine, and glutamate in children with autism spectrum disorders.","volume":"42","author":"Tirouvanziam","year":"2012","journal-title":"J Autism Dev Disord"},{"key":"R16-3-20210203","first-page":"113","article-title":"Plasma excitatory amino acids in autism.","volume":"37","author":"Moreno-Fuenmayor","year":"1996","journal-title":"Invest Clin"},{"key":"R17-3-20210203","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1023\/A:1022238706604","article-title":"Plasma amino acid levels in children with autism and their families.","volume":"33","author":"Aldred","year":"2003","journal-title":"J Autism Dev Disord"},{"issue":"3","key":"R18-3-20210203","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/01.jcp.0000270082.30500.69","article-title":"Glutamate antagonists seem to be slightly effective in psychopharmacologic treatment of autism.","volume":"27","author":"Niederhofer","year":"2007","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"R19-3-20210203","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/nrd3761","article-title":"Neurodevelopmental disorders: glutamate blockers show benefit in models of autism spectrum disorders.","volume":"11","author":"Harrison","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"R20-3-20210203","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.pnpbp.2010.07.005","article-title":"Double-blind, placebo-controlled trial of risperidone plustopiramate in children with autistic disorder.","volume":"34","author":"Rezaei","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"4","key":"R21-3-20210203","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1017\/S1461145712000880","article-title":"Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial.","volume":"16","author":"Ghaleiha","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"key":"R22-3-20210203","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40272-013-0036-2","article-title":"Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial.","volume":"15","author":"Ghaleiha","year":"2013","journal-title":"Paediatr Drugs"},{"key":"R23-3-20210203","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/WNF.0b013e3182a9339d","article-title":"Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study.","volume":"36","author":"Mohammadi","year":"2013","journal-title":"Clin Neuropharmacol"},{"key":"R24-3-20210203","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.plefa.2005.06.002","article-title":"Increased excretion of a lipid peroxidation biomarker in autism.","volume":"73","author":"Ming","year":"2005","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"issue":"5","key":"R25-3-20210203","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1179\/1351000211Y.0000000012","article-title":"Urinary oxidative stress markers in children with autism.","volume":"16","author":"Damodaran","year":"2011","journal-title":"Redox Rep"},{"key":"R26-3-20210203","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12011-011-9280-x","article-title":"Increased markers of oxidative stress in autistic children of the Sultanate of Oman.","volume":"147","author":"Essa","year":"2012","journal-title":"Biol Trace Elem Res"},{"key":"R27-3-20210203","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1096\/fj.08-128926","article-title":"Cellular and mitochondrial glutathione redox imbalance in lymphoblastoid cells derived from children with autism.","volume":"23","author":"James","year":"2009","journal-title":"FASEB J"},{"key":"R28-3-20210203","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1471-2377-11-139","article-title":"Novel metabolic biomarkers related to sulfur-dependent detoxification pathways in autistic patients of Saudi Arabia.","volume":"11","author":"Al-Yafee","year":"2011","journal-title":"BMC Neurol"},{"issue":"8","key":"R29-3-20210203","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1007\/s11064-012-0775-4","article-title":"Brain region-specific glutathione redox imbalance in autism.","volume":"37","author":"Chauhan","year":"2012","journal-title":"Neurochem Res"},{"key":"R30-3-20210203","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s11689-011-9077-4","article-title":"Glutathione pathway gene variation and risk of autism spectrum disorders.","volume":"3","author":"Bowers","year":"2012","journal-title":"J Neurodev Disord"},{"key":"R31-3-20210203","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/ajmg.b.30366","article-title":"Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism.","volume":"141","author":"James","year":"2006","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"R32-3-20210203","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1054\/plef.2002.0439","article-title":"Investigation of antioxidant enzymes in children with autistic disorder.","volume":"67","author":"Yorbik","year":"2002","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"R33-3-20210203","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12011-010-8840-9","article-title":"Evaluation of oxidative stress in autism: defective antioxidant enzymes and increased lipid peroxidation.","volume":"143","author":"Meguid","year":"2011","journal-title":"Biol Trace Elem Res"},{"key":"R34-3-20210203","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.brainres.2011.06.063","article-title":"Amelioration of behavioral aberrations and oxidative markers by green tea extract in valproate induced autism in animals.","volume":"1410","author":"Banji","year":"2011","journal-title":"Brain Res"},{"key":"R35-3-20210203","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/0891-5849(89)90066-X","article-title":"The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid.","volume":"6","author":"Aruoma","year":"1989","journal-title":"Free Radic Biol Med"},{"issue":"2","key":"R36-3-20210203","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1503\/jpn.100057","article-title":"N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action.","volume":"36","author":"Dean","year":"2011","journal-title":"J Psychiatry Neurosci"},{"issue":"3","key":"R37-3-20210203","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.tips.2013.01.001","article-title":"The promise of N-acetylcysteine in neuropsychiatry.","volume":"34","author":"Berk","year":"2013","journal-title":"Trends Pharmacol Sci"},{"issue":"11","key":"R38-3-20210203","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.biopsych.2012.01.014","article-title":"A randomized controlled pilot trial of oral N-acetylcysteine in children with autism.","volume":"71","author":"Hardan","year":"2012","journal-title":"Biol Psychiatry"},{"key":"R39-3-20210203","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/1471-244X-13-196","article-title":"A randomized double blind placebo controlled clinical trial of N-acetylcysteine added to risperidone for treating autistic disorders.","volume":"13","author":"Ghanizadeh","year":"2013","journal-title":"BMC Psychiatry"},{"issue":"5","key":"R40-3-20210203","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/BF02172145","article-title":"Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders.","volume":"24","author":"Lord","year":"1994","journal-title":"J Autism Dev Disord"},{"key":"R41-3-20210203","first-page":"485","article-title":"The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects.","volume":"89","author":"Aman","year":"1985","journal-title":"Am J Ment Defic"},{"key":"R42-3-20210203","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.pnpbp.2009.09.012","article-title":"Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism.","volume":"34","author":"Akhondzadeh","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"7","key":"R43-3-20210203","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1177\/0269881113508830","article-title":"Galantamine efficacy and tolerability as an augmentative therapy in autistic children: a randomized, double-blind, placebo-controlled trial.","volume":"28","author":"Ghaleiha","year":"2013","journal-title":"J Psychopharmacol"},{"key":"R44-3-20210203","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00213-012-2796-8","article-title":"Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial.","volume":"225","author":"Asadabadi","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"R45-3-20210203","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1089\/cap.2008.0123","article-title":"Omega 3 fatty acid treatment in autism.","volume":"19","author":"Meiri","year":"2009","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"R46-3-20210203","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10803-010-1078-8","article-title":"A pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder.","volume":"41","author":"Bent","year":"2011","journal-title":"J Autism Dev Disord"},{"issue":"5","key":"R47-3-20210203","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/0278-5846(93)90058-Z","article-title":"A preliminary trial of ascorbic acid as supplemental therapy for autism.","volume":"17","author":"Dolske","year":"1993","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"4","key":"R48-3-20210203","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1515\/BC.2003.059","article-title":"Glutathione pathways in the brain.","volume":"384","author":"Dringen","year":"2003","journal-title":"Biol Chem"},{"issue":"20","key":"R49-3-20210203","doi-asserted-by":"crossref","first-page":"9134","DOI":"10.1523\/JNEUROSCI.22-20-09134.2002","article-title":"The origin and neuronal function of in vivo nonsynaptic glutamate.","volume":"22","author":"Berk","year":"2002","journal-title":"J Neurosci"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WNF.0000000000000063","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:10:00Z","timestamp":1620976200000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-201501000-00003"}},"subtitle":["A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Efficacy and Safety"],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0000000000000063","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]}}}